A Phase 1 interventional study of Rifampin and Vemurafenib in Malignant Melanoma, Neoplasms, sponsored by Hoffmann-La Roche. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-15.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing vemurafenib in Melanoma — 2 open to participants now, 2 under way, 1 of them phase 3. Vemurafenib · Melanoma.
Among the 56 studies testing vemurafenib in Melanoma, this one is the 23rd largest by enrollment, is one of 18 that started in 2013, is one of 26 in phase 1, and was the 26th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →2 of the 56 studies testing vemurafenib in Melanoma are open now, in 2 countries. Recruiting first, the newest first:
Cancer Research UK · Sites in United Kingdom
Ages 18+
University of Louisville · Sites in United States
Ages 18+
By country, each count listing its studies:
Vemurafenib: first FDA approval 2011 (ZELBORAF), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 25 · Phase 3 5 · Phase 4 1
First in 2006; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 18 across the 56 interventional studies. Of the 49 that completed or were terminated, 30 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 56 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
57 studies in Melanoma by Hoffmann-La Roche: none open now, 4 under way, none of them phase 3. Of 52 finished, 34 (65%) have results posted.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 36th largest by enrollment of the 52 interventional ones that give a count, is one of 12 that started in 2013, is one of 27 in phase 1, and was the 23rd registered.
Hoffmann-La Roche’s Melanoma studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 56 studies testing vemurafenib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 57 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multi-center, three-period, one-sequence study will investigate the effect of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF without acceptable standard treatment options. Eligible participants will have the option to continue treatment with vemurafenib as part of an extension study GO28399 (NCT01739764).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
Drug: Rifampin · Drug: Vemurafenib
Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
Also known as: RO5185426, Zelboraf
Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib
AUClast is the area under the vemurafenib plasma concentration versus time curve from time zero to the time of last measured concentration of vemurafenib (Tlast). Area under the curve (AUC) is a measure of the plasma concentration of a drug over time. AUClast is presented in micrograms times (\*) hour per milliliter (mcg\*h/mL).
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib
AUC(0-inf) is the AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). AUC is a measure of the plasma concentration of a drug over time. AUC(0-inf) is presented in mcg\*h/mL.
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Maximum Observed Plasma Concentration (Cmax) of Vemurafenib
Cmax is the maximum observed plasma vemurafenib concentration, presented in microgram per milliliter (mcg/mL).
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Time to Reach Cmax (Tmax) of Vemurafenib
Tmax is the time from vemurafenib administration to reach Cmax for vemurafenib.
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Plasma Elimination Half Life (t1/2) of Vemurafenib
Plasma elimination half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Plasma Apparent Clearance (CL/F) of Vemurafenib
Clearance of a drug is a measure of the rate at which a drug is removed (metabolized or eliminated by normal biological processes) from the blood. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Area Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib
AUC(0-168) is the AUC from time zero (pre-dose) to 168 hours (time point for last blood sample collection). AUC is a measure of the plasma concentration of a drug over time. AUC(0-168) is presented in mcg\*h/mL.
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Percent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib
The AUCpeo, that is, percent area obtained after extrapolation from Tlast to infinity is calculated by using the formula AUCpeo = 100\*(AUC\[0-inf\] minus AUC\[0-last\])/AUC(0-inf). This parameter provides information about what percentage of the theoretical curve AUC(0-inf) is possible to determine experimentally (AUC0-last).
Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
| Milestone | Vemurafenib + Rifampin (All Periods) |
|---|---|
| Started | 27 |
| Completed | 24 |
| Not completed | 3 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 2 |
AUClast is the area under the vemurafenib plasma concentration versus time curve from time zero to the time of last measured concentration of vemurafenib (Tlast). Area under the curve (AUC) is a measure of the plasma concentration of a drug over time. AUClast is presented in micrograms times (\*) hour per milliliter (mcg\*h/mL).
| mcg*h/mL | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib | 125 ± 101.4 | 76.7 ± 75.3 |
AUC(0-inf) is the AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). AUC is a measure of the plasma concentration of a drug over time. AUC(0-inf) is presented in mcg\*h/mL.
| mcg*h/mL | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib | 131 ± 104.2 | 78.1 ± 74.3 |
Cmax is the maximum observed plasma vemurafenib concentration, presented in microgram per milliliter (mcg/mL).
| mcg/mL | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Vemurafenib | 4.45 ± 63.3 | 4.95 ± 59.1 |
Tmax is the time from vemurafenib administration to reach Cmax for vemurafenib.
| hours | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Time to Reach Cmax (Tmax) of Vemurafenib | 4.00 (1.98 to 7.92) | 4.00 (1.98 to 6.02) |
Plasma elimination half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.
| hours | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Plasma Elimination Half Life (t1/2) of Vemurafenib | 29.7 ± 17.6 | 11.6 ± 5.24 |
Clearance of a drug is a measure of the rate at which a drug is removed (metabolized or eliminated by normal biological processes) from the blood. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| liters/hour | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Plasma Apparent Clearance (CL/F) of Vemurafenib | 7.35 ± 104.2 | 12.3 ± 74.3 |
AUC(0-168) is the AUC from time zero (pre-dose) to 168 hours (time point for last blood sample collection). AUC is a measure of the plasma concentration of a drug over time. AUC(0-168) is presented in mcg\*h/mL.
| mcg*h/mL | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Area Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib | 126 ± 99.6 | 78.0 ± 74.2 |
The AUCpeo, that is, percent area obtained after extrapolation from Tlast to infinity is calculated by using the formula AUCpeo = 100\*(AUC\[0-inf\] minus AUC\[0-last\])/AUC(0-inf). This parameter provides information about what percentage of the theoretical curve AUC(0-inf) is possible to determine experimentally (AUC0-last).
| percent AUC | Vemurafenib (Intervention Period A) | Vemurafenib + Rifampin (Intervention Period C) |
|---|---|---|
| Percent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib | 2.75 ± 150.4 | 1.26 ± 95.9 |
Collected over Day 1 up to 28 days after last dose of study drug (up to 51 days overall). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vemurafenib (Intervention Period A) | — | 0/27 (0%) | 4/27 (14.8%) |
| Rifampin (Intervention Period B) | — | 0/26 (0%) | 8/26 (30.8%) |
| Vemurafenib + Rifampin (Intervention Period C) | — | 2/25 (8%) | 5/25 (20%) |
| Vemurafenib + Rifampin (All Periods) | — | 2/27 (7.4%) | 12/27 (44.4%) |
| Event | Vemurafenib (Intervention Period A) | Rifampin (Intervention Period B) | Vemurafenib + Rifampin (Intervention Period C) | Vemurafenib + Rifampin (All Periods) |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/27 | 0/26 | 1/25 | 1/27 |
| Confusional statePsychiatric disorders | 0/27 | 0/26 | 1/25 | 1/27 |
| Event | Vemurafenib (Intervention Period A) | Rifampin (Intervention Period B) | Vemurafenib + Rifampin (Intervention Period C) | Vemurafenib + Rifampin (All Periods) |
|---|---|---|---|---|
| ChromaturiaRenal and urinary disorders | 0/27 | 5/26 | 0/25 | 5/27 |
| HeadacheNervous system disorders | 2/27 | 2/26 | 3/25 | 4/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/27 | 2/26 | 0/25 | 3/27 |
| NauseaGastrointestinal disorders | 0/27 | 0/26 | 2/25 | 2/27 |
| ConstipationGastrointestinal disorders | 0/27 | 2/26 | 0/25 | 2/27 |
| DiarrhoeaGastrointestinal disorders | 1/27 | 0/26 | 1/25 | 2/27 |
| Decreased appetiteMetabolism and nutrition disorders | 0/27 | 1/26 | 1/25 | 2/27 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/27 | 0/26 | 1/25 | 2/27 |
The intent-to-treat (ITT) population included all participants who were enrolled in the study.
| Age, Continuous(years) | Vemurafenib + Rifampin (All Periods) |
|---|---|
| Mean | 57.9 ± 13.0 |
| Sex: Female, Male(Participants) | Vemurafenib + Rifampin (All Periods) |
|---|---|
| Female | 9 |
| Male | 18 |
The record gives a start of Jul 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rifampin · Vemurafenib